{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:04Z","timestamp":1791846124160,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ajur.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T19:36:11Z","timestamp":1733772971000},"page":"309-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Diego","family":"Parrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemecio","family":"Lizana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina B.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Larra\u00f1aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario I.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Crist\u00f3bal","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2024.08.005_bib1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.who.int\/today. [Accessed 10 August 2024]."},{"key":"10.1016\/j.ajur.2024.08.005_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-023-10798-2","article-title":"Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajur.2024.08.005_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/cancers15041323","article-title":"Approaches to clinical complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer: possibilities and limitations","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajur.2024.08.005_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib7","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2024.08.005_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib9","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib10","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.5152\/tud.2020.20337","article-title":"Guideline of guidelines: muscle-invasive bladder cancer","volume":"47","author":"Omorphos","year":"2021","journal-title":"Turk J Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of life after radical cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ajur.2024.08.005_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajur.2024.08.005_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.21037\/tau-23-124","article-title":"Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives","volume":"12","author":"Fan","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/SPC.0000000000000579","article-title":"Bladder preservation in urothelial carcinoma: current trends and future directions","volume":"15","author":"Goodstein","year":"2021","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ajur.2024.08.005_bib17","article-title":"Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajur.2024.08.005_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/14737140.2018.1535314","article-title":"Trimodal therapy for muscle-invasive bladder cancer","volume":"18","author":"Mathes","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ajur.2024.08.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Ruiz de Porras","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajur.2024.08.005_bib20","series-title":"Bladder cancer: diagnosis and management","year":"2015"},{"key":"10.1016\/j.ajur.2024.08.005_bib21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s11864-023-01113-z","article-title":"Perioperative immunotherapy in muscle-invasive bladder cancer","volume":"24","author":"Singh","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ajur.2024.08.005_bib23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajur.2024.08.005_bib24","article-title":"Cochrane methods","year":"2016"},{"key":"10.1016\/j.ajur.2024.08.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"10.1016\/j.ajur.2024.08.005_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ciresp.2013.08.002","article-title":"[GRADE system: classification of quality of evidence and strength of recommendation]","volume":"92","author":"Aguayo-Albasini","year":"2014","journal-title":"Cir Esp"},{"key":"10.1016\/j.ajur.2024.08.005_bib27","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs. random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Global Spine J"},{"key":"10.1016\/j.ajur.2024.08.005_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib29","article-title":"Survival after radical cystectomy: progressive versus de novo muscle invasive bladder cancer","volume":"25","author":"Vlaming","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ajur.2024.08.005_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.08.005_bib32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib33","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clgc.2018.09.023","article-title":"Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer","volume":"17","author":"Royce","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ajur.2024.08.005_bib36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajur.2024.08.005_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5489\/cuaj.7430","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Canadian cost-effectiveness analysis","volume":"16","author":"Kool","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ajur.2024.08.005_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/UPJ.0000000000000403","article-title":"Cost of bladder cancer care: a single-center comparison of radical cystectomy and trimodal therapy","volume":"10","author":"Magee","year":"2023","journal-title":"Urol Pract"},{"key":"10.1016\/j.ajur.2024.08.005_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","article-title":"Life and death of SPARE (Selective Bladder Preservation Against Radical Excision): reflections on why the SPARE trial closed","volume":"106","author":"Huddart","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.08.005_bib40","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ajur.2024.08.005_bib41","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.14109","article-title":"Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer","volume":"121","author":"Ritch","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.08.005_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ajur.2024.08.005_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/BLC-200303","article-title":"Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: a comparative survival analysis of treatment modalities in the national cancer database","volume":"6","author":"Pfail","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ajur.2024.08.005_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/6972703","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib47","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ajur.2024.08.005_bib48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0269215517692129","article-title":"Where have all the pilot studies gone? A follow-up on 30 years of pilot studies in clinical rehabilitation","volume":"31","author":"Kaur","year":"2017","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.ajur.2024.08.005_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajur.2024.08.005_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ajur.2024.08.005_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512311","article-title":"The bladder tumor microenvironment components that modulate the tumor and impact therapy","volume":"24","author":"Patwardhan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2024.08.005_bib52","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ajur.2024.08.005_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","article-title":"Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG Oncology RTOG 0524\u2014a phase 1\/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation","volume":"7","author":"Dahl","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajur.2024.08.005_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","article-title":"Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib56","doi-asserted-by":"crossref","first-page":"S1332","DOI":"10.1016\/j.annonc.2022.07.1817","article-title":"1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)","volume":"33","author":"Weickhardt","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4588","article-title":"Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: an interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4)","volume":"40","author":"Vazquez-Estevez","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib58","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2021.39.15_suppl.4505","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial","volume":"39","author":"Garcia del Muro","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib59","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.annonc.2020.08.848","article-title":"776P phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized\/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]","volume":"31","author":"Vaishampayan","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib60","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1200\/JCO.2022.40.16_suppl.4589","article-title":"Phase II clinical study of tislelizumab combined with nab-paclitaxel (TRUCE-01) for muscle-invasive urothelial bladder carcinoma: bladder preservation subgroup analysis","volume":"40","author":"Niu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12664-020-01107-x","article-title":"Basics of meta-analysis","volume":"39","author":"Shah","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.ajur.2024.08.005_bib62","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijrobp.2022.07.1831","article-title":"An introduction to meta-analysis","volume":"115","author":"Lehrer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajur.2024.08.005_bib63","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.3390\/curroncol30120740","article-title":"Identifying optimal candidates for trimodality therapy among nonmetastatic muscle-invasive bladder cancer Patients","volume":"30","author":"Ran","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib64","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE\u2014a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.08.005_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","article-title":"A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)","volume":"41","author":"Geynisman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2024.08.005_bib67","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijrobp.2022.07.475","article-title":"INTACT (S\/N1806): phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014toxicity update on first 213 patients","volume":"114","author":"Singh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajur.2024.08.005_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.08.005_bib69","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388224001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388224001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:06:48Z","timestamp":1757776008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388224001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2214388224001358"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2024.08.005","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}